said that its Clinical Research Organization, AnaCipher, located at Hyderabad successfully cleared the United States Food and Drug Administration (USFDA) inspection with zero 483s. The inspection was held from October 14-18, 2019.
Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited said, “This achievement is for the fifth time in a row and confirms the capabilities of our team at the CRO for maintaining highest quality standards and excellence in servicing our clients”.
The CRO - AnaCipher conducts Bio-Equivalence and Bio-Availability (BA/BE) studies at its facility in Hyderabad and is spread over an area of 30,000 sq. ft. with 98 beds.
Indoco Remedies Ltd is currently trading at Rs152.35 up by Rs8 or 5.54% from its previous closing of Rs144.35 on the BSE.
The scrip opened at Rs145 and has touched a high and low of Rs154.70 and Rs144.30 respectively.